Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are ...

The presentation scheduled for Tuesday, February 11th at 12:40-1:10 PM ET in Track 1 will feature a business overview and update by Miranda Toledano, the Company’s Chief Executive Officer.

The drugs include Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets and the company is the exclusive ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral tablet, ASC30, in obese individuals. The study, which involved 40 obese ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Fruit juice, honey, hard candies, and glucose tablets can treat low blood sugar levels between 55-69 milligrams per deciliter. Severely low blood sugar usually requires a glucagon injection.

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.